全文获取类型
收费全文 | 2575篇 |
免费 | 166篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 169篇 |
妇产科学 | 37篇 |
基础医学 | 307篇 |
口腔科学 | 52篇 |
临床医学 | 237篇 |
内科学 | 521篇 |
皮肤病学 | 28篇 |
神经病学 | 126篇 |
特种医学 | 499篇 |
外科学 | 232篇 |
综合类 | 40篇 |
一般理论 | 1篇 |
预防医学 | 159篇 |
眼科学 | 22篇 |
药学 | 118篇 |
中国医学 | 4篇 |
肿瘤学 | 196篇 |
出版年
2022年 | 11篇 |
2021年 | 23篇 |
2020年 | 19篇 |
2019年 | 19篇 |
2018年 | 27篇 |
2017年 | 25篇 |
2016年 | 32篇 |
2015年 | 38篇 |
2014年 | 46篇 |
2013年 | 90篇 |
2012年 | 80篇 |
2011年 | 70篇 |
2010年 | 104篇 |
2009年 | 89篇 |
2008年 | 81篇 |
2007年 | 78篇 |
2006年 | 81篇 |
2005年 | 60篇 |
2004年 | 55篇 |
2003年 | 55篇 |
2002年 | 46篇 |
2001年 | 44篇 |
2000年 | 57篇 |
1999年 | 56篇 |
1998年 | 142篇 |
1997年 | 123篇 |
1996年 | 132篇 |
1995年 | 96篇 |
1994年 | 80篇 |
1993年 | 87篇 |
1992年 | 48篇 |
1991年 | 48篇 |
1990年 | 44篇 |
1989年 | 85篇 |
1988年 | 64篇 |
1987年 | 71篇 |
1986年 | 60篇 |
1985年 | 56篇 |
1984年 | 35篇 |
1983年 | 40篇 |
1982年 | 36篇 |
1981年 | 21篇 |
1980年 | 38篇 |
1979年 | 16篇 |
1978年 | 22篇 |
1977年 | 22篇 |
1976年 | 30篇 |
1975年 | 25篇 |
1972年 | 7篇 |
1965年 | 6篇 |
排序方式: 共有2766条查询结果,搜索用时 15 毫秒
1.
G M Novotny 《The Journal of otolaryngology》1989,18(7):354-356
In 17 cases the author has removed intraglandular submandibular calculi by an oral route utilizing blunt soft tissue dissection after an incision of the mucosa only. General anesthesia is used and the patient discharged after an overnight stay. No complications were encountered. All patients were back on full diet in 48 hours. 相似文献
2.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
3.
JA HYEON KU CHEOL KWAK SEUNG-JUNE OH EUNSIK LEE SANG EUN LEE JAE-SEUNG PAICK 《International journal of urology》2004,11(7):489-493
BACKGROUND: Our aims in the present study were to estimate the influences of pain and urinary symptoms on quality of life, and to determine which of these two variables has the most predictive power with respect to quality of life in young men with chronic prostatitis-like symptoms. METHODS: Chronic prostatitis-like symptoms were measured by the National Institutes of Health-Chronic Prostatitis Symptom Index. Of the 28,841 men aged 20 years who lived in the study community, 18,495 men (a response rate 64.1%) agreed to participate in the study. A total of 1057 men who complained of symptoms indicative of chronic prostatitis were included in the study. The influences of pain and urinary symptoms on quality of life were determined using logistic regression analysis. The receiver operating characteristic (ROC) curve was used to estimate the predictive ability of each of these variables with respect to quality of life. RESULTS: Results from multivariate analysis showed that both pain and urinary symptoms were associated with an increased likelihood of impaired quality of life, although pain contributed more to a reduced quality of life than urinary symptoms. Relative to men who experienced mild pain, men who experienced moderate pain had a 3.9-fold risk of poor quality of life (odds ratio [OR], 3.87; 95% confidence interval [CI], 2.86-5.23; P < 0.001) and those who experienced severe pain had a 15.7-fold risk of reduced quality of life (OR, 15.68; 95% CI, 6.59-37.35; P < 0.001). Moderate urinary symptoms were associated with a 1.4-fold risk of bother (OR, 1.41; 95% CI, 1.01-1.99; P < 0.001) and severe urinary symptoms were associated with 2.4-fold risk (OR, 2.39; 95% CI, 1.37-4.12; P < 0.001), relative to mild urinary symptoms. Comparison of the effects of pain and urinary symptoms showed that pain severity had the most predictive power for bother, quality of life, and quality-of-life impact. The areas under the ROC curves for bother, quality of life, and quality-of-life impact were 71.3%, 69.3% and 72.5%, respectively. CONCLUSION: Urinary symptoms and pain might be associated with an increased likelihood of impaired quality of life in young men with chronic prostatitis-like symptoms. In addition, our findings suggest that pain severity is the most influential variable for determining quality of life in this population. 相似文献
4.
5.
6.
7.
8.
9.
10.
Localized 1H NMR spectra of glutamate in the human brain. 总被引:2,自引:0,他引:2
D L Rothman C C Hanstock O A Petroff E J Novotny J W Prichard R G Shulman 《Magnetic resonance in medicine》1992,25(1):94-106
Localized 1H NMR spectra at TE = 12 ms were obtained from cerebral cortex of human subjects using ISIS with surface suppression. The 2.29-ppm resonance was assigned to C4 glutamate with contributions from C4 glutamine and GABA using in vivo spectral editing and comparison of chemical shift with pure compounds. The measured intensity ratio between the 2.29 resonance and the creatine resonance at 3.03 ppm was in good agreement with the ratio predicted from previously reported measurements of glutamate, glutamine, and GABA concentrations in biopsied human brain tissue. 相似文献